Asset Details
Do you wish to reserve the book?
Targeting the extrinsic apoptosis signaling pathway for cancer therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting the extrinsic apoptosis signaling pathway for cancer therapy
Do you wish to request the book?
Targeting the extrinsic apoptosis signaling pathway for cancer therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting the extrinsic apoptosis signaling pathway for cancer therapy
2011
Overview
The extrinsic apoptosis pathway is triggered by the binding of death ligands of the tumor necrosis factor (TNF) family to their appropriate death receptors (DRs) on the cell surface. One TNF family member, TNF-related apoptosis-inducing ligand (TRAIL or Apo2L), seems to preferentially cause apoptosis of transformed cells and can be systemically administered in the absence of severe toxicity. Therefore, there has been enthusiasm for the use of TRAIL or agonist antibodies to the TRAIL DR4 and DR5 in cancer therapy. Nonetheless, many cancer cells are very resistant to TRAIL apoptosis in vitro. Therefore, there is much interest in identifying compounds that can be combined with TRAIL to amplify its apoptotic effects. In this review, I will provide a brief overview of apoptosis signaling by TRAIL and discuss apoptosis-sensitizing agents, focusing mainly on the proteasome inhibitor bortezomib (VELCADE) and some novel sensitizers that we have recently identified. Alternative ways to administer TRAIL or DR agonist antibodies as therapeutic agents will also be described. Finally, I will discuss some of the gaps in our understanding of TRAIL apoptosis signaling and suggest some research directions that may provide additional information for optimizing the targeting of the extrinsic apoptosis pathway for future cancer therapy.
Publisher
Springer-Verlag,Springer,Springer Nature B.V
Subject
Adjuvants, Immunologic - therapeutic use
/ Animals
/ Antibodies, Monoclonal - pharmacology
/ Antibodies, Monoclonal - therapeutic use
/ Biological and medical sciences
/ Boronic Acids - pharmacology
/ Boronic Acids - therapeutic use
/ Humans
/ Ligands
/ Medicine
/ Oncology
/ Pharmacology. Drug treatments
/ Proteins
/ Receptors, Tumor Necrosis Factor - immunology
/ Signal Transduction - immunology
/ TNF-Related Apoptosis-Inducing Ligand - agonists
/ TNF-Related Apoptosis-Inducing Ligand - therapeutic use
/ Toxicity
